ReviewMolecular oral microbiology2026
Host-Microbe Mechanisms of Fusobacterium nucleatum in Colorectal Cancer.
Review in Molecular oral microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The oral-derived pathobiont Fusobacterium nucleatum has increasingly been implicated in colorectal cancer (CRC) progression through its ability to modulate inflammatory, immunological, and molecular pathways. F. nucleatum has emerged as a key oral-derived pathobiont frequently associated with tumor aggressiveness and alterations in the colorectal tumor microenvironment. This review critically examines recent mechanistic evidence from in vitro, in vivo, and advanced experimental models to elucidate how F. nucleatum interacts with host pathways involved in colorectal carcinogenesis. Available evidence indicates that this bacterium actively reshapes the tumor microenvironment through coordinated effects on immune signaling, epigenetic regulation, metabolic adaptation, and metastatic competence. Mechanistically, F. nucleatum promotes sustained inflammatory activation, macrophage polarization, epithelial-mesenchymal transition, endothelial remodeling, and resistance to regulated cell death pathways, while also influencing transcriptional and oncogenic programs associated with tumor progression. Emerging evidence further suggests that microbial effects may be modulated by tumor heterogeneity and long-term environmental exposures, reinforcing the complexity of host-microbiome interactions in CRC. Collectively, the findings support the concept that F. nucleatum functions as an active biological driver rather than a passive microbial bystander in CRC progression. These insights highlight the translational relevance of tumor-associated microbiota and support the need for approaches combining mechanistic, microbial, and clinical data to refine precision strategies at the tumor-microbiome interface.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.